JP2018538287A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538287A5 JP2018538287A5 JP2018529219A JP2018529219A JP2018538287A5 JP 2018538287 A5 JP2018538287 A5 JP 2018538287A5 JP 2018529219 A JP2018529219 A JP 2018529219A JP 2018529219 A JP2018529219 A JP 2018529219A JP 2018538287 A5 JP2018538287 A5 JP 2018538287A5
- Authority
- JP
- Japan
- Prior art keywords
- mrna
- protein
- item
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022000102A JP2022046723A (ja) | 2015-12-14 | 2022-01-04 | 多発性嚢胞腎の処置のためのアンチセンスオリゴマー |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267252P | 2015-12-14 | 2015-12-14 | |
| US62/267,252 | 2015-12-14 | ||
| PCT/US2016/066417 WO2017106211A1 (en) | 2015-12-14 | 2016-12-13 | Antisense oligomers for treatment of polycystic kidney disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000102A Division JP2022046723A (ja) | 2015-12-14 | 2022-01-04 | 多発性嚢胞腎の処置のためのアンチセンスオリゴマー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018538287A JP2018538287A (ja) | 2018-12-27 |
| JP2018538287A5 true JP2018538287A5 (https=) | 2020-01-30 |
Family
ID=59057523
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529219A Withdrawn JP2018538287A (ja) | 2015-12-14 | 2016-12-13 | 多発性嚢胞腎の処置のためのアンチセンスオリゴマー |
| JP2022000102A Pending JP2022046723A (ja) | 2015-12-14 | 2022-01-04 | 多発性嚢胞腎の処置のためのアンチセンスオリゴマー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000102A Pending JP2022046723A (ja) | 2015-12-14 | 2022-01-04 | 多発性嚢胞腎の処置のためのアンチセンスオリゴマー |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3389782A4 (https=) |
| JP (2) | JP2018538287A (https=) |
| CA (1) | CA3005247A1 (https=) |
| WO (1) | WO2017106211A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| CN107109411B (zh) | 2014-10-03 | 2022-07-01 | 冷泉港实验室 | 核基因输出的定向增加 |
| EP3359685B1 (en) | 2015-10-09 | 2026-01-28 | University Of Southampton | Modulation of gene expression for deregulated protein expression |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| EP3933041B1 (en) | 2015-12-14 | 2024-01-31 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant retardation |
| SG11202001590RA (en) | 2017-08-25 | 2020-03-30 | Stoke Therapeutics Inc | Antisense oligomers for treatment of conditions and diseases |
| US12060558B2 (en) | 2018-05-04 | 2024-08-13 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| EP4017979A4 (en) * | 2019-08-19 | 2024-03-27 | Stoke Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATING PROTEIN SPLICING AND EXPRESSION |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
| AU2022215577A1 (en) * | 2021-02-03 | 2023-09-21 | Stoke Therapeutics, Inc. | Compositions for treatment of conditions and diseases associated with polycystin expression |
| IL324441A (en) * | 2023-06-16 | 2026-01-01 | Pyc Therapeutics Ltd | Compounds and methods for treating kidney diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040102402A1 (en) * | 2002-11-22 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of tissue factor expression |
| US8007790B2 (en) * | 2006-04-03 | 2011-08-30 | Stowers Institute For Medical Research | Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases |
| WO2008094194A2 (en) * | 2006-07-24 | 2008-08-07 | Athena Diagnostics, Inc. | Pkd mutations and evaluation of same |
| US20150141320A1 (en) * | 2012-05-16 | 2015-05-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
| PL3041958T4 (pl) * | 2013-09-04 | 2020-11-02 | Cold Spring Harbor Laboratory | Redukcja rozpadu mRNA mediowanego sekwencjami nonsensownymi |
| CN107109411B (zh) * | 2014-10-03 | 2022-07-01 | 冷泉港实验室 | 核基因输出的定向增加 |
-
2016
- 2016-12-13 JP JP2018529219A patent/JP2018538287A/ja not_active Withdrawn
- 2016-12-13 WO PCT/US2016/066417 patent/WO2017106211A1/en not_active Ceased
- 2016-12-13 CA CA3005247A patent/CA3005247A1/en active Pending
- 2016-12-13 EP EP16876500.6A patent/EP3389782A4/en not_active Withdrawn
-
2022
- 2022-01-04 JP JP2022000102A patent/JP2022046723A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018538287A5 (https=) | ||
| JP2018538288A5 (https=) | ||
| JP2019501892A5 (https=) | ||
| JP2019500347A5 (https=) | ||
| JP2019500350A5 (https=) | ||
| JP2022062140A5 (https=) | ||
| JP7420679B2 (ja) | 状態および疾患の処置のためのアンチセンスオリゴマー | |
| JP2019500346A5 (https=) | ||
| JP2019500349A5 (https=) | ||
| JP2017536338A5 (https=) | ||
| JP2019500345A5 (https=) | ||
| KR20080031164A (ko) | ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절 | |
| US9353169B2 (en) | Means and methods for modulating NOTCH3 protein expression and/or the coding region of NOTCH3; compositions and use thereof in the treatment of CADASIL | |
| CA3140045A1 (en) | Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of use | |
| JPWO2019181946A1 (ja) | 毒性が軽減した核酸 | |
| US20200407721A1 (en) | Compounds of chemically modified oligonucleotides and methods of use thereof | |
| JP2024079818A (ja) | コレステリルエステル蓄積症の処置のための方法及び組成物 | |
| JP2021523227A5 (https=) | ||
| CN121079413A (zh) | 编辑rna的方法、组合物及其应用 | |
| TW202242113A (zh) | 用於治療與多囊蛋白表現相關之病況及疾病之組合物 | |
| JPWO2019213525A5 (https=) | ||
| EP3746555B1 (en) | Inhibition of a lncrna for treatment of neuroblastoma | |
| KR20250122542A (ko) | 넌센스 매개 rna 분해 기반 병태 및 질환의 치료를 위한 안티센스 올리고머 | |
| JP2025533501A (ja) | ポンペ病マウスモデルの生成、特徴決定および使用方法 | |
| JPWO2022169947A5 (https=) |